Aller au contenu principal
xMedica

NCT07784270ClinicalTrials.gov

A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight

A Phase III Randomized, Double-Blind, Placebo-Controlled Multicentre Trial to Evaluate the Efficacy and Safety of AZD6234 in Participants With Type 2 Diabetes Mellitus and Obesity or Overweight (SELENE 2)

En recrutementAccepte des participants actuellement, selon la fiche du registre.
Contacter cette étude

En bref

The study will evaluate how well AZD6234 works and how safe it is in adults with excess weight or obesity. Efficacy of AZD6234 will be compared to placebo in percent body weight change from baseline at 68 weeks of treatment

Phase 31 500 participants recherchés230 sites16 pays

Catégories

Enregistré dans 1 registre

Une même étude peut être enregistrée dans plusieurs registres. Nous l'affichons une seule fois et renvoyons vers chaque fiche que nous détenons.

Les informations de l'essai sont affichées telles que publiées par le registre, dans leur langue d'origine.

Cette étude vous intéresse ?

Se connecter ou créez un compte pour manifester votre intérêt et suivre cette étude.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Not stated: Registered after enrolment began (about 5 days after the recorded start)First posted 2026-08-25; recorded start 2026-08-20
  • Present: Has a defined primary outcomeA primary outcome measure is listed in the record
  • Present: The primary outcome states a time frameThe primary outcome measure records a time frame
  • Present: Participants are randomly assignedAllocation is recorded as randomised
  • Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
  • Present: Uses blinding (masking)A masking level is recorded in the record
  • Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Present: Sponsor has 1038 other studies in this databaseCounted from the lead sponsor named in the record (AstraZeneca)
  • Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
  • The record lists 2 conditions.
  • Lead sponsor type recorded as: industry.
  • Intervention regulatory context: investigational, within a phased regulatory pathway.

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourSTRONG

A strong methodological design for a phase 3 study, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation20/20

    Participants are randomly allocated between arms

  • Blinding20/20

    Quadruple-blind

  • Control arm13/15

    Placebo / sham control arm

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type3/10

    Surrogate or intermediate endpoint (conservative default)

  • Multi-centre8/8

    Multi-centre: 218 sites

  • Data monitoring committee0/7

    No data monitoring committee stated

  • Prospective registration5/5

    Registered before the study start date

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleLARGE

A large study, international in scope: 1,500 participants (target), run at 230 sites, across 16 countries.

How this score is built
  • Enrolment32/40

    1,500 participants (target)

  • Site count25/25

    218 sites

  • Country count15/15

    16 countries

  • Planned duration7/10

    Planned over about 24 months

  • Sponsor scale10/10

    AstraZeneca has led 1,017 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

Résumé

The study will evaluate how well AZD6234 works and how safe it is in adults with excess weight or obesity. Efficacy of AZD6234 will be compared to placebo in percent body weight change from baseline at 68 weeks of treatment

This is a Phase III, global, randomized, parallel-group, double-blind, multicentre study to assess the efficacy and safety of AZD6234 compared with placebo in adults with Type 2 Diabetes Mellitus (T2DM) and obesity or overweight. Eligible participants will be randomized to either receive AZD6234 or matching placebo respectively.

Affections

  • Obesity or Overweight
  • Diabetes Mellitus, Type 2

Éligibilité

Éligibilité
SexeTous
Âges18 Years – Aucun maximum
Volontaires sainsNon

Éligibilité telle qu'elle figure dans le registre

Inclusion Criteria: * Males \& females (inclusive of all gender identities) age ≥18 years * BMI ≥27 kg/m2 * Diagnosed with T2DM ≥90 days prior to Screening * HbA1c value at Screening of ≥6.0% (42 mmol/mol) and ≤10% (86 mmol/mol) managed with diet and exercise alone or with a stable dose of any oral glycaemic-lowering agent (as per local labelling) * Stable body weight (≤5% body weight change) for at least 3 months prior to Randomisation * History of at least one self-reported unsuccessful attempt to lose body weight in lifetime Exclusion Criteria: * Obesity primarily caused by other endocrine disorders * Type 1 diabetes mellitus (or any other diabetes mellitus that is not clearly Type 2 diabetes), OR have history of ketoacidosis or hyperosmolar coma/state within 3 months prior to Screening * Significant hepatobiliary disease and/or any of the following results at Screening: * ALT ≥ 3.0 X ULN * AST ≥ 3.0 X ULN * TBL \> 1.5 X ULN (except for cases of known Gilbert's Syndrome) * Has received treatment with a GLP-1 receptor agonist or GLP-1 containing medication for any indication within 3 months before Randomisation * Use of insulin therapy for T2DM within 3 months prior to screening

Éligibilité en énoncés simples

Les critères de cette fiche n'ont pas encore été décomposés en énoncés distincts. Le texte du registre ci-dessus est complet et fait foi.

Conception de l'étude

Conception de l'étude
Type d'étudeInterventionnelle
PhasePhase 3
RépartitionRandomisée
Modèle d'interventionPARALLEL
Objectif principalTREATMENT
InsuQUADRUPLE (4)
Recrutement1 500 participants recherchés

Promoteur et collaborateurs

  • AstraZeneca Promoteur

Groupes et interventions

  • AZD6234 Dose 1EXPERIMENTAL

    AZD6234 Dose 1

  • AZD6234 Dose 2EXPERIMENTAL

    AZD6234 Dose 2

  • PlaceboPLACEBO_COMPARATOR

    Matching placebo

Interventions

  • Médicament Lenbelintide

    IMP injected subcutaneously, once a week. Unit dose strength as per CSP.

  • Médicament Placebo

    Placebo matching IMP dose injected subcutaneously, once a week.

Critères de jugement

  1. Critère de jugement principal

    Percent change in body weight from baseline at 68 weeks of treatment.

    To evaluate the effect of AZD6234 compared to placebo in percent body weight change

    Délai 68 weeks

  2. Critère de jugement secondaire

    Absolute change in weight (kg) from baseline at 68 weeks of treatment

    To evaluate the effect of AZD6234 compared to placebo on absolute change in weight

    Délai 68 weeks

  3. Critère de jugement secondaire

    Achievement of at least 5 % body weight loss from baseline at 68 weeks of treatment

    To evaluate the effect of AZD6234 compared to placebo in body weight loss of at least 5%

    Délai 68 weeks

  4. Critère de jugement secondaire

    Achievement of at least 10 % body weight loss from baseline at 68 weeks of treatment

    To evaluate the effect of AZD6234 compared to placebo in body weight loss of at least 10%

    Délai 68 weeks

  5. Critère de jugement secondaire

    Change in haemoglobin A1C from baseline at 68 weeks of treatment

    To evaluate the effect of AZD6234 on haemoglobin A1C change

    Délai 68 weeks

  6. Critère de jugement secondaire

    Change in waist circumference (cm) from baseline at 68 weeks of treatment

    To evaluate the effect of AZD6234 compared to placebo on waist circumference change

    Délai 68 weeks

  7. Critère de jugement secondaire

    Percent change in triglycerides from baseline at 68 weeks of treatment

    To evaluate the effect of AZD6234 compared to placebo on triglycerides percent change

    Délai 68 weeks

  8. Critère de jugement secondaire

    Change in systolic blood pressure (mmHg) from baseline at 68 weeks of treatment

    To evaluate the effect of AZD6234 compared to placebo on systolic blood pressure change

    Délai 68 weeks

  9. Critère de jugement secondaire

    Percent change in fat mass from baseline at 68 weeks of treatment measured by DXA in the DXA Sub-Study subset

    Body Composition Sub-study: To evaluate the effect of AZD6234 compared to placebo on body composition change in the DXA subset of participants

    Délai 68 weeks

Dates

Dates
Date de début20 août 2026 (réelle)
Achèvement principal9 août 2028 (estimée)
Achèvement9 août 2028 (estimée)
Première publication25 août 2026 (réelle)
Dernière mise à jour28 octobre 2026
Résultats publiésNon précisé dans la fiche du registre
Statut vérifié pour la dernière foisoctobre 2026

Réelle signifie que l'événement a eu lieu. Estimée signifie que le promoteur s'y attend. Les deux ont un sens différent.

Lieux

58 sites sont en recrutement

Argentina

Argentina
ÉtablissementVilleÉtat ou régionStatut
Research SiteBuenos AiresEn recrutement
Research SiteCABAEn recrutement
Research SiteCiudad de Buenos AiresEn recrutement
Research SiteMendozaEn recrutement
Research SiteRamos MejíaPas encore en recrutement
Research SiteRosarioEn recrutement
Research SiteSan NicolásPas encore en recrutement

Australia

Australia
ÉtablissementVilleÉtat ou régionStatut
Research SiteBotanyEn recrutement
Research SiteCamberwellEn recrutement
Research SiteCharlestownEn recrutement
Research SiteHelensvaleEn recrutement
Research SiteMaroubraEn recrutement
Research SiteWaitaraEn recrutement

Canada

Canada
ÉtablissementVilleÉtat ou régionStatut
Research SiteCalgaryAlbertaEn recrutement
Research SiteHamiltonOntarioEn recrutement
Research SiteJolietteQuebecEn recrutement
Research SiteMarkhamOntarioEn recrutement
Research SiteMonctonNew BrunswickEn recrutement
Research SiteMontrealQuebecEn recrutement
Research SiteMontrealQuebecEn recrutement
Research SiteNorth YorkOntarioEn recrutement
Research SiteQuébecQuebecEn recrutement
Research SiteSarniaOntarioEn recrutement
Research SiteScarborough VillageOntarioEn recrutement
Research SiteStoney CreekOntarioRetiré
Research SiteStouffvilleOntarioEn recrutement
Research SiteTorontoOntarioEn recrutement
Research SiteTorontoOntarioEn recrutement
Research SiteTrois-RivièresQuebecEn recrutement
Research SiteTruroNova ScotiaEn recrutement
Research SiteVancouverBritish ColumbiaEn recrutement

Chile

Chile
ÉtablissementVilleÉtat ou régionStatut
Research SiteConcepciónPas encore en recrutement
Research SiteConcepciónPas encore en recrutement
Research SiteConcepciónPas encore en recrutement
Research SiteIquiquePas encore en recrutement
Research SiteLas CondesPas encore en recrutement
Research SiteProvidenciaPas encore en recrutement
Research SiteSantiagoPas encore en recrutement
Research SiteSantiagoPas encore en recrutement
Research SiteSantiagoPas encore en recrutement

China

China
ÉtablissementVilleÉtat ou régionStatut
Research SiteBeijingPas encore en recrutement
Research SiteCangzhouPas encore en recrutement
Research SiteChangchunPas encore en recrutement
Research SiteChengduPas encore en recrutement
Research SiteChengduPas encore en recrutement
Research SiteDanyangPas encore en recrutement
Research SiteGanzhouPas encore en recrutement
Research SiteGuangzhouPas encore en recrutement
Research SiteHuizhouPas encore en recrutement
Research SiteHuzhouPas encore en recrutement

180 sites supplémentaires sont indiqués dans la fiche du registre.

Documents de l'étude

Aucun document n'est lié dans cette fiche du registre.

Évolution au fil du temps

  1. 28 octobre 2026

    Date d'achèvement reportée

    Primary completion delayed 1 days

    2028-08-082028-08-09

  2. 28 octobre 2026

    Site ajouté

    3 sites added (230 total)

    227230

  3. 22 septembre 2026

    Statut modifié

    Status changed from Not yet recruiting to Recruiting

    NOT_YET_RECRUITINGRECRUITING

  4. 22 septembre 2026

    Recrutement ouvert

    Recruitment opened

    NOT_YET_RECRUITINGRECRUITING

  5. 22 septembre 2026

    Date d'achèvement avancée

    Primary completion advanced 1 days

    2028-08-092028-08-08

  6. 22 septembre 2026

    Site ajouté

    9 sites added (227 total)

    218227